RVMD
Revolution Medicines, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 2.20M | $451.04M | n/a | n/a |
| Q2 2026 | 149 | +17 | 106.82M | $18.63B | +25 | −7 |
| Q1 2026 | 134 | +17 | 103.45M | $9.43B | +22 | −6 |
| Q4 2025 | 116 | +1 | 107.70M | $8.12B | +3 | −1 |
| Q3 2025 | 20 | +3 | 68.96M | $3.10B | +3 | −1 |
| Q2 2025 | 15 | 0 | 63.88M | $2.26B | n/a | n/a |
| Q1 2025 | 12 | +2 | 32.32M | $1.05B | +2 | n/a |
| Q4 2024 | 10 | -1 | 33.19M | $1.34B | n/a | −1 |
| Q3 2024 | 10 | -1 | 26.28M | $1.08B | n/a | −1 |
| Q2 2024 | 11 | n/a | 28.23M | $999.53M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 13.66M | n/a | $530.15M | 0.1% | n/c | 1 | SEC ↗ ×8 |
| 2 | T. Rowe Price ✦ | 5.82M | n/a | $202.50M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 3 | Geode Capital Management ✦ (passive) | 3.34M | n/a | $129.48M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 1.85M | n/a | $71.75M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 816.05K | n/a | $31.67M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 439.12K | n/a | $15.87M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 7 | Point72 Asset Management ✦ | 227.92K | n/a | $8.85M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 670.00K | n/a | $6.65M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | D. E. Shaw & Co. ✦ | 1.38M | n/a | $1.23M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 10 | Two Sigma Investments ✦ | 22.76K | n/a | $883,199 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 12.83K | n/a | $498,010 | 0.0% | n/c | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 509 holders, 197.96M shares, $18.53B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 765 sh · $158,600
Officer · 3.12K sh · $625,885
Officer · 587 sh · $117,400
Director · 910 sh · $174,585
Director · 4.99K sh · $959,805
Director · 1.50K sh · $291,883
Director · 100 sh · $19,515
Director · 2.65K sh · $512,227
Officer · 1.76K sh · $347,402
Officer, Director · 13.78K sh · $2.75M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology